Bolland MJ, et al. - Results of a 4-year extension of a 2-year randomized placebo-controlled trial showed that in HIV-infected men the antiresorptive impacts of two annual 4 mg doses of zoledronate endured for at least 5 years after the second dose, so researchers assessed if the impacts on BMD and bone turnover persisted beyond 10 years. The authors concluded that two annual 4 mg doses of zoledronate have effects on bone turnover and BMD in men that endure after the second dose for at least 11 years. BMD remained higher in the zoledronate group than the placebo group, and the between-group differences in BMD remained stable between 6 and 12 years.